A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
It is a randomized, double-blinded, parallel, single-dose, PhaseⅠcomparative study to evaluate the pharmacokinetics and safety of QL2108 to Dupixent® in healthy Chinese adult subjects. A total of 198 healthy subjects are planned to be included and randomized at a ratio of 1:1 to receive single 300mg/2.0ml QL2108 injection or Dupixent®.
Epistemonikos ID: 76799f153e0ec91f8c82af5143c76fe8312bbdd8
First added on: Oct 01, 2024